Skip to main content
Log in

‘Let’s fix the chemical imbalance first, and then we can work on the problems second’: an exploration of ethical implications of prescribing an SSRI for ‘depression’

  • Published:
Monash Bioethics Review Aims and scope Submit manuscript

Abstract

The creation of pharmacotherapies, such as Selective Serotonin Reuptake Inhibitors (SSRIs), for the treatment of depression was hailed as a great breakthrough in mental health care. However, since that time, serious questions have arisen as to their safety and the way they are prescribed without full information being provided to patients about a range of important issues, including the possible aetiologies of depression, and the efficacy and potential side-effects of medication. These issues have been especially important in the care and treatment of young people, as there is evidence that SSRIs may be implicated in increased suicidal behaviour. In this article, we examine the experiences of five individuals who were prescribed an SSRI in their late teens or early twenties, and discuss some of the ethical issues that arise from their accounts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chur-Hansen, A., Zion, D. ‘Let’s fix the chemical imbalance first, and then we can work on the problems second’: an exploration of ethical implications of prescribing an SSRI for ‘depression’. Monash Bioethics Review 25, 15–30 (2006). https://doi.org/10.1007/BF03351444

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03351444

Keywords

Navigation